Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTYLUNG: ctDNA to Predict Immunotherapy Response in Metastatic NSCLC
NCT04790682Recruiting
- Sponsor
- Institut Curie
- Start
- May 2021
- Primary completion
- Jun 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Institut Curie. Primary endpoint: ctDNA variation of the prominent mutant allele variation at 6 weeks. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04790682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790682.